Key Points
- Eric Swayze sold 15,642 shares of Ionis on Feb. 13 at an average price of $81.76 for about $1.28M, trimming his holdings to 32,105 shares (a 32.76% reduction).
- Significant recent insider selling: Swayze has sold roughly 55,217 shares across January–February transactions, totaling about $4.4M in proceeds.
- Stock context: IONS traded near $80.60 (close to its 1‑year high of $86.74) and carries a consensus analyst target of $86.95 with a "Moderate Buy" rating.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) Director B Lynne Parshall sold 5,000 shares of the firm's stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $82.72, for a total transaction of $413,600.00. Following the completion of the sale, the director owned 56,344 shares in the company, valued at $4,660,775.68. This represents a 8.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Ionis Pharmaceuticals Trading Down 1.4%
NASDAQ IONS opened at $80.60 on Friday. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The firm has a market cap of $13.06 billion, a PE ratio of -47.69 and a beta of 0.29. The company has a 50 day moving average price of $80.70 and a 200 day moving average price of $69.12. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.74.
Analysts Set New Price Targets
Several brokerages have recently commented on IONS. Raymond James Financial reiterated a "strong-buy" rating and set a $89.00 price objective (up previously from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. Piper Sandler upped their target price on Ionis Pharmaceuticals from $77.00 to $87.00 and gave the company an "overweight" rating in a research report on Friday, February 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Ionis Pharmaceuticals in a research note on Thursday, January 22nd. Morgan Stanley boosted their price target on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an "overweight" rating in a research note on Thursday, October 30th. Finally, HC Wainwright upped their price objective on shares of Ionis Pharmaceuticals from $100.00 to $110.00 and gave the company a "buy" rating in a report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Ionis Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $86.95.
Read Our Latest Analysis on Ionis Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Brown Brothers Harriman & Co. purchased a new position in shares of Ionis Pharmaceuticals in the fourth quarter worth about $27,000. Golden State Wealth Management LLC increased its holdings in Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company's stock worth $25,000 after buying an additional 250 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new position in Ionis Pharmaceuticals during the 3rd quarter worth approximately $25,000. Mather Group LLC. acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Finally, Quarry LP purchased a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $38,000. 93.86% of the stock is owned by institutional investors and hedge funds.
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
